title: Improved glycemic control with teneligliptin in patients with type 2 diabetes mellitus on hemodialysis: Evaluation by continuous glucose monitoring.
abstract: OBJECTIVE
  Recent reports suggest that appropriate glycemic control without hypoglycemia could decrease mortality in patients with diabetes mellitus (DM) and end-stage renal disease (ESRD). However, an indication of oral anti-diabetic drugs is limited in this population. The aim of this study was to evaluate efficacy of teneligliptin, a novel DPP-4 inhibitor, by continuous glucose monitoring (CGM) in patients with type 2 DM (T2DM) on hemodialysis (HD).
  
  
  METHODS
  This 4-week, open label, single arm, intervention trial included 10 diabetic patients undergoing HD and with glycated albumin (GA) level of ≥18.3%. Teneligliptin treatment was administered on days with HD sessions (HD day) and on days without HD sessions (NHD day); blood glucose values were measured by CGM. The primary endpoint was improvement of glycemic control evaluated by area under the curve (AUC). As secondary endpoints, changes in GA, HbA1c and fasting plasma glucose (FPG) were evaluated.
  
  
  RESULTS
  Teneligliptin improved blood glucose AUC on both HD days (p=0.004), and NHD days (p=0.004). This was accompanied by a significant reduction in GA, HbA1c, and FPG, without severe hypoglycemia.
  
  
  CONCLUSIONS
  Teneligliptin is one of the useful options for glycemic control in T2DM patients undergoing HD.
authors: Department of Internal Medicine, Minami-Osaka Hospital, Osaka, Japan.
authors: Noritsugu
authors: N
authors: Wada
authors: Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan. Electronic address: ktmori@med.osaka-cu.ac.jp.
authors: Katsuhito
authors: K
authors: Mori
authors: Department of Internal Medicine, Minami-Osaka Hospital, Osaka, Japan.
authors: Chie
authors: C
authors: Nakagawa
authors: Department of Internal Medicine, Minami-Osaka Hospital, Osaka, Japan.
authors: Jun
authors: J
authors: Sawa
authors: Department of Internal Medicine, Minami-Osaka Hospital, Osaka, Japan.
authors: Yasuro
authors: Y
authors: Kumeda
authors: Department of Geriatrics and Vascular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan.
authors: Tetsuo
authors: T
authors: Shoji
authors: Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan.
authors: Masanori
authors: M
authors: Emoto
authors: Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan.
authors: Masaaki
authors: M
authors: Inaba
mesh_terms: D000284:Administration, Oral; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000628:therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D017127:Glycation End Products, Advanced; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control; D007003:Hypoglycemia / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D007564:Japan; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D018670:Monitoring, Ambulatory; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006435:Renal Dialysis; D012709:Serum Albumin / Q000032:analysis; D000075462:Serum Albumin, Human; D012720:Severity of Illness Index; D053778:Thiazolidines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000093423:Glycated Serum Albumin
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006442:Glycated Hemoglobin; D017127:Glycation End Products, Advanced; D011720:Pyrazoles; D012709:Serum Albumin; D000075462:Serum Albumin, Human; D053778:Thiazolidines; D000093423:Glycated Serum Albumin; C579035:3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine; C422455:ALB protein, human; C517652:hemoglobin A1c protein, human
keywords: Diabetic nephropathy; ESRD; Hemodialysis; Teneligliptin; Type 2 diabetes